Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Accumulated Expenses: 2022-2023

Historic Other Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 1 years, with Mar 2023 value amounting to $2.3 million.

  • InMed Pharmaceuticals' Other Accumulated Expenses was N/A to $2.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2022, which is N/A change from last year.
  • Per InMed Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $2.3 million for Q1 2023, which was down 5.46% from $2.4 million recorded in Q4 2022.
  • InMed Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $3.3 million for Q3 2022, and its period low was $2.3 million during Q1 2023.
  • Its 2-year average for Other Accumulated Expenses is $2.8 million, with a median of $2.8 million in 2022.